OICC Press Progress in Biomaterials 2194-0517 13 03 2024 09 30 Development and Evaluation of Biocompatible Scaffolds for Chronic Wound Healing and Biomaterials: Incorporating Vancomycin and Graphene Oxide 10.57647/pibm.2024.132409 EN Alireza Jangi Department of Biomedical Engineering, SR.C., Islamic Azad University, Tehran, Iran Azadeh Asefnejad Department of Biomedical Engineering, SR.C., Islamic Azad University, Tehran, Iran Shahrokh Shojaei Department of Biomedical Engineering, CT.C., Islamic Azad University, Tehran, Iran Hessam Rezaei Department of Biomedical Engineering, SR.C., Islamic Azad University, Tehran, Iran Mohammad Mohammadi Department of Biomedical Engineering, SR.C., Islamic Azad University, Tehran, Iran Sara Gholizadeh Department of Aesthetic and Restorative Dentistry, Faculty of Dentistry, Isf.C, Islamic Azad University, Isfahan, Iran Foad Iranmanesh Department of Endodontic, School of Dentistry, Rafsanjan University of Medical Sciences, Rafsanjan, Iran Journal Article 2024 09 30 Chronic wounds represent a considerable challenge for healthcare systems, necessitating the identification of effective wound  dressings to facilitate healing. This study aimed to develop scaffolds utilizing biocompatible materials such as albumin and gelatin,  with the incorporation of vancomycin for its antibacterial properties and graphene oxide nanoparticles to enhance mechanical  strength. The scaffolds were fabricated through a freeze-drying technique and subsequently evaluated for morphology using  scanning electron microscopy (SEM), functional groups via Fourier-transform infrared spectroscopy (FTIR), and assessed for swelling, biodegradability, along with various mechanical, biological, and antibacterial properties. The release profile of vancomycin from the G.5%Al.3%Go scaffold exhibited a more controlled pattern compared to that of the G.5%Al.1%Go scaffold. Additionally, immersion of the scaffolds in phosphate-buffered saline for 30 minutes indicated that increased graphene oxide content  correlated with reduced swelling. Over a 15-day period, the degradation rate of the scaffolds revealed that the G.10%Al.3%Go scaffold degraded by up to 35%, while the G.5%Al.1%Go scaffold showed the lowest degradation rate at 18%. These results shows that the G.10%Al.3%Go scaffold may serve as a promising candidate for atopic treatment.